Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.47 |
| ▸ | PGR | P06401 | 3/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | PDIA6 | Q15084 | 1/20 | 0.34 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3227515 | 0.91 | PTGS2 (0.47) | PTGS2PTGS1PGRBRAFTNKS2 | |
| SCHEMBL7001431 | 0.90 | PTGS2 (0.46) | PTGS2PTGS1PGRBRAF | |
| SCHEMBL6999265 | 0.90 | PTGS2 (0.53) | PTGS2PTGS1PGRPDE3BPDE3A | |
| SCHEMBL6999166 | 0.90 | PTGS2 (0.39) | PTGS2PTGS1PGRBRAFPDIA6 | |
| SCHEMBL3232556 | 0.89 | PTGS2 (0.45) | PTGS2PTGS1PGRBRAF | |
| SCHEMBL6995305 | 0.87 | MAOB (0.41) | PTGS2PTGS1PDIA6CA1CA2 | |
| Polmacoxib SCHEMBL3233093 | 0.85 | PTGS2 (0.55) | PTGS2PTGS1PGRCA1CA2 | |
| Polmacoxib SCHEMBL29351757 | 0.85 | PTGS2 (0.55) | PTGS2PTGS1PGRCA1CA2 | |
| SCHEMBL6996672 | 0.83 | PTGS2 (0.51) | PTGS2PTGS1PGR | |
| SCHEMBL6997576 | 0.83 | PTGS2 (0.53) | PTGS2PTGS1PGRBRAFTNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069483-A1 | DUAL INHIBITION OF CYCLOOXYGENASE-2 AND CARBONIC ANHYDRASE | AMOREPACIFIC CORPORATION (KR) | 2010-03-18 | — | — | US | claimed |
| WO-2005094815-A1 | DUAL INHIBITION OF CYCLOOXYGENASE-2 AND CARBONIC ANHYDRASE | AMOREPACIFIC CORPORATION (KR) | 2005-10-13 | — | — | WO | claimed |
| US-20050222251-A1 | Dual inhibition of cyclooxygenase-2 and carbonic anhydrase | AMOREPACIFIC CORPORATION | 2005-10-06 | — | — | US | claimed |
| EP-1109799-B1 | 4,5-DIARYL-3(2H)-FURANONE DERIVATIVES AS CYCLOOXYGENASE-2 INHIBITORS | PACIFIC CORP (KR) | 2003-12-17 | — | — | EP | claimed |
| US-6492416-B1 | TREATING INFLAMMATION AND ASSOCIATED DISORDERS | PACIFIC CORPORATION (KR) | 2002-12-10 | — | — | US | claimed |
| US-20100069483-A1 | DUAL INHIBITION OF CYCLOOXYGENASE-2 AND CARBONIC ANHYDRASE | AMOREPACIFIC CORPORATION (KR) | 2010-03-18 | — | — | US | disclosed |
| WO-2005094815-A1 | DUAL INHIBITION OF CYCLOOXYGENASE-2 AND CARBONIC ANHYDRASE | AMOREPACIFIC CORPORATION (KR) | 2005-10-13 | — | — | WO | disclosed |
| US-20050222251-A1 | Dual inhibition of cyclooxygenase-2 and carbonic anhydrase | AMOREPACIFIC CORPORATION | 2005-10-06 | — | — | US | disclosed |
| EP-1109799-B1 | 4,5-DIARYL-3(2H)-FURANONE DERIVATIVES AS CYCLOOXYGENASE-2 INHIBITORS | PACIFIC CORP (KR) | 2003-12-17 | — | — | EP | disclosed |
| US-6492416-B1 | TREATING INFLAMMATION AND ASSOCIATED DISORDERS | PACIFIC CORPORATION (KR) | 2002-12-10 | — | — | US | disclosed |
| EP-1109799-A1 | 4,5-DIARYL-3(2H)-FURANONE DERIVATIVES AS CYCLOOXYGENASE-2 INHIBITORS | PACIFIC CORPORATION (KR) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000061571-A1 | 4,5-DIARYL-3(2H)-FURANONE DERIVATIVES AS CYCLOOXYGENASE-2 INHIBITORS | PACIFIC CORPORATION (KR) | 2000-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222251-A1 | Dual inhibition of cyclooxygenase-2 and carbonic anhydrase | PTGS2, CA2, PTGES2 | PTGS2 1/4885PTGS1 4/4885PGR 3427/4885 |
| US-20100069483-A1 | DUAL INHIBITION OF CYCLOOXYGENASE-2 AND CARBONIC ANHYDRASE | PTGS2, CA2, PTGES2 | PTGS2 1/4885PTGS1 4/4885PGR 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.